Diabetic retinopathy is a major cause worldwide of vision loss from diabetic maculopathy or proliferative retinopathy. Without widely accepted classifications of diabetic retinopathy and diabetic maculopathy, it is difficult to compare results of clinical trials or monitor clinical care. The European School of Advanced Studies in Ophthalmology has developed an international classification of diabetic maculopathy based upon spectral domain optical coherence tomography, which could be helpful for both initial evaluation and subsequent follow-up of diabetic patients in both clinical practice and experimental trials.
Diabetic retinopathy (DR) is a major cause worldwide of vision loss from diabetic macular edema (DME) or proliferative retinopathy. Although effective treatments exist, primarily laser photocoagulation or anti-vascular endothelial growth factor (VEGF) injections, a worldwide epidemic of obesity is fueling an increasing incidence of diabetes and DR. Without widely accepted classifications of DR and DME, it is difficult to compare results of clinical trials or monitor clinical care, even with huge amounts of data now available in registries.
In 1968, Morton Goldberg and Stuart Fine organized a meeting at Airlie House, Virginia, to discuss the management of DR. 1 The state of knowledge of DR was revie wed by experts, and out of that meeting, a classification emerged. Subsequently, this classification was modified for use by the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS). 2 This classification system, often called the Diabetic Retinopathy Severity Scale (DRSS), grades retinopathy from no retinopathy (level 10) to advanced proliferative retinopathy (level 95). The numerical grading is complex. The distinction between each grade and the next grade is not uniform in terms of severity, and the numbers are unevenly distributed from levels 10 to 95. It was based solely upon stereoscopic color fundus photographs. At that time, fluorescein angiography was not felt to add to the predictive value of the photographs.
Since that time, the DRSS has been widely used in clinical trials. However, it has never been widely applied in clinical care and-I have to admit-before I became the Chair of the DRCR Retina Network, I did not use this scale and I was unfamiliar with its numbers. An international classification with greater simplicity was put forward in 2003, 3 and other subsequent classifications have evolved, largely based on color photographs.
At present, the major shortcoming of these classifications is that we have new advanced imaging modalities that are not utilized, especially optical coherence tomography (OCT). Structural OCT can beautifully document retinal thickness, cysts changes in the macula, as well as exudates, hyperreflective foci, disruption of the inner retinal architecture, damage to the external limiting membrane (ELM) and the ellipsoid zone, and subretinal fluid. Other recent advances have included the development of widefield color fundus photography, widefield fluorescein angiography, and most recently, OCT angiography and adaptive optics. Clinicians and researchers would benefit from a classification scheme utilizing many of these parameters, but at present, this does not exist. It will be difficult to mesh the information provided by the various modalities.
Structural spectral domain and swept source OCT central subfield thickness is now widely used as indication for the need for additional treatment (decision-making) for DME. However, it has been recognized in recent years that there is only a mild-to-moderate correlation between central subfield thickness and visual acuity. 4 This applies to baseline findings as well as final outcomes; the reasons for this have been previously discussed in some detail. 5 Spectral domain and swept source OCT images contain much more information than retinal thickness. Early attempts at OCT classification of DME were based on time domain OCT. 6 The European School of Advanced Studies in Ophthalmology (ESASO) has now created a classification of diabetic maculopathy (DM) based purely upon spectral domain OCT. It utilizes seven distinct features of an OCT structural image going through the center of the fovea. These include foveal thickness or macular volume (T), intraretinal cysts (C), the ellipsoid zone (EZ) or ELM status (E), presence of disorganization of retinal inner layers (DRIL) (D), number of hyperreflective foci (H), subfoveal fluid (F), and vitreoretinal changes (V). Each feature is given a numerical rating. These are not intended to be additive, but rather a separate evaluation of each of these findings. It is somewhat akin to the rating of cancer types and stages. In clinical trials, it will be easy for a reading center to evaluate these seven parameters. The ESASO hopes that it will also be helpful for clinical care, both initial evaluation and subsequent follow-up. While we await more complex multi-modal classifications, researchers and clinicians should try this classification to evaluate its utility.
